Eledon Pharmaceuticals Stock Performance
| ELDN Stock | USD 3.61 0.10 2.85% |
The firm shows a Beta (market volatility) of 1.54, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Eledon Pharmaceuticals will likely underperform. At this point, Eledon Pharmaceuticals has a negative expected return of -0.21%. Please make sure to confirm Eledon Pharmaceuticals' potential upside, and the relationship between the jensen alpha and daily balance of power , to decide if Eledon Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Eledon Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 2.85 | Five Day Return 1.98 | Year To Date Return (15.85) | Ten Year Return (99.83) | All Time Return (99.91) |
Last Split Factor 1:18 | Dividend Date 2020-10-05 | Last Split Date 2020-10-05 |
1 | Acquisition by Kirk Allan of 3430 shares of Eledon Pharmaceuticals subject to Rule 16b-3 | 01/10/2025 |
2 | Acquisition by Gros David-alexandre C of 66500 shares of Eledon Pharmaceuticals subject to Rule 16b-3 | 01/13/2025 |
3 | Acquisition by Robinson James A. Jr. of 30870 shares of Eledon Pharmaceuticals at 4.04 subject to Rule 16b-3 | 01/14/2025 |
4 | Acquisition by Bvf Partners L Pil of 1031385 shares of Eledon Pharmaceuticals at 2.37 subject to Rule 16b-3 | 01/31/2025 |
5 | Acquisition by Gros David-alexandre C of 1015743 shares of Eledon Pharmaceuticals at 2.3 subject to Rule 16b-3 | 02/25/2025 |
| Begin Period Cash Flow | 4.6 M |
Eledon |
Eledon Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 427.00 in Eledon Pharmaceuticals on December 24, 2024 and sell it today you would lose (66.00) from holding Eledon Pharmaceuticals or give up 15.46% of portfolio value over 90 days. Eledon Pharmaceuticals is currently does not generate positive expected returns and assumes 3.5313% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Eledon, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Eledon Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eledon Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Eledon Pharmaceuticals, and traders can use it to determine the average amount a Eledon Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0608
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ELDN |
Estimated Market Risk
| 3.53 actual daily | 31 69% of assets are more volatile |
Expected Return
| -0.21 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Eledon Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eledon Pharmaceuticals by adding Eledon Pharmaceuticals to a well-diversified portfolio.
Eledon Pharmaceuticals Fundamentals Growth
Eledon Stock prices reflect investors' perceptions of the future prospects and financial health of Eledon Pharmaceuticals, and Eledon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eledon Stock performance.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 76.43 M | ||||
| Shares Outstanding | 59.74 M | ||||
| Price To Book | 1.83 X | ||||
| EBITDA | (36.86 M) | ||||
| Net Income | (36.18 M) | ||||
| Cash And Equivalents | 70.46 M | ||||
| Cash Per Share | 5.12 X | ||||
| Total Debt | 954 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 22.22 X | ||||
| Book Value Per Share | 1.85 X | ||||
| Cash Flow From Operations | (47.27 M) | ||||
| Earnings Per Share | (0.75) X | ||||
| Market Capitalization | 215.66 M | ||||
| Total Asset | 177.41 M | ||||
| Retained Earnings | (355.59 M) | ||||
| Working Capital | 132.15 M | ||||
About Eledon Pharmaceuticals Performance
By examining Eledon Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Eledon Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Eledon Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.3 K | 1.7 K | |
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.45) | (0.48) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.30) | (0.31) |
Things to note about Eledon Pharmaceuticals performance evaluation
Checking the ongoing alerts about Eledon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eledon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eledon Pharmaceuticals generated a negative expected return over the last 90 days | |
| Eledon Pharmaceuticals has high historical volatility and very poor performance | |
| Net Loss for the year was (36.18 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eledon Pharmaceuticals currently holds about 70.46 M in cash with (47.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.12, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eledon Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Roughly 68.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Robinson James A. Jr. of 30870 shares of Eledon Pharmaceuticals at 4.04 subject to Rule 16b-3 |
- Analyzing Eledon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eledon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Eledon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eledon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eledon Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eledon Pharmaceuticals' stock. These opinions can provide insight into Eledon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.